Differences between Istradefylline Responders and Non-Responders in Parkinson’s Disease

• 作者: Asako Yoritaka Nobutaka Hattori
• 来源期刊: 帕金森(英文)
• 学科: 医学
• 关键词: Parkinson’s Disease Istradefylline ADENOSINE A2A Receptor ANTAGONIST Wearing-Off SLEEPINESS
• 年，卷（期）: 2017,（2）
• 页码范围: 45-51
• 页数: 7页
• 分类号: R73

摘要

Background: Istradefylline is a selective adenosine A2A receptor antagonist approved for Parkinson’s disease (PD) patients with wearing-off symptoms. The Japanese phase III trial showed that 20 mg of orally administrated istradefylline decreased the Off-time. However, istradefylline showed prominent effects in some patients and no benefits in others. We examined the differences in characteristics between responders and non-responders who received 8 weeks of 20 mg/day istradefylline. Methods: Thirty-one patients were enrolled (age, 65.4 [SD 10.4] years;disease duration, 10.4 [SD 6.1] years;daily levodopa dosage, 553.2 [SD 228.7] mg;frequency of levodopa consumption, 4.7 [SD 1.5] times;levodopa equivalent dose, 811.2 [SD 307.5] mg). Results: There were significant differences (p Conclusions: Younger or female patients who are not excessively sleepy during daytime are better candidates for the istradefylline therapy.